In a report released yesterday, Marc Goodman from SVB Securities reiterated a Buy rating on Evolus (EOLS - Research Report), with a price target of $18.00. The company's shares closed yesterday at $7.07.Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Axsome Therapeutics, and Biogen. According to TipRanks, Goodman has an average return of -1.0% and a 41.53% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolus with a $16.00 average price target, implying a 126.31% upside from current levels.
https://www.tipranks.com/news/blurbs/svb-securities-sticks-to-its-buy-rating-for-evolus-eols?utm_source=advfn.com&utm_medium=referral
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Aug 2023 to Sep 2023 Click Here for more Evolus Charts.
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Sep 2022 to Sep 2023 Click Here for more Evolus Charts.